NCT04555837 2025-05-20Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerM.D. Anderson Cancer CenterPhase 1/2 Completed24 enrolled 13 charts
NCT01045421 2016-08-15Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal MalignanciesMillennium Pharmaceuticals, Inc.Phase 1/2 Completed273 enrolled 28 charts